Stock 9969 INNOCARE PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company InnoCare Pharma Limited

Equities

9969

KYG4783B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:16 02/05/2024 BST 		5-day change 1st Jan Change
5.24 HKD +13.17% Intraday chart for InnoCare Pharma Limited +24.17% -23.95%
03-29 InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib CI
03-28 Transcript : InnoCare Pharma Limited, 2023 Earnings Call, Mar 28, 2024

Business Summary

InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.

Number of employees: 1,089

Sales per Business

HKD in Million2022Weight2023Weight Delta
Biopharmaceutical Research and Development, Manufacturing, Commercialization and Services
100.0 %
727 100.0 % 816 100.0 % +12.21%

Sales per region

HKD in Million2022Weight2023Weight Delta
China
91.1 %
661 90.8 % 744 91.1 % +12.60%
Overseas
8.9 %
67 9.2 % 72 8.9 % +8.33%

Managers

Managers TitleAgeSince
Jisong Cui CEO
 Chief Executive Officer 62 02/11/15
Xin Fu DFI
 Director of Finance/CFO 46 12-17
Kevin Gao COO
 Chief Operating Officer - -
Xiang Yang Zhang CTO
 Chief Tech/Sci/R&D Officer - 28/02/21
Chen Xiang Yang CTO
 Chief Tech/Sci/R&D Officer 58 30/09/15
Zhao Renbin BRD
 Director/Board Member 55 02/11/15
Norman Kong PRN
 Corporate Officer/Principal - -
Jessie Wang LAW
 General Counsel - -
Xiaodong Jin PRN
 Corporate Officer/Principal 52 27/06/20
Manish Tandon PRN
 Corporate Officer/Principal - 10/10/20

Members of the board

Members of the board TitleAgeSince
Yigong Shi FOU
 Founder 57 02/11/15
Kai Xian Chen BRD
 Director/Board Member 79 29/02/20
Jisong Cui CEO
 Chief Executive Officer 62 02/11/15
Lan Hu BRD
 Director/Board Member 53 10/03/20
Zhao Renbin BRD
 Director/Board Member 55 02/11/15
Dan Dan Dong BRD
 Director/Board Member 40 10/10/23
Rong Gang Xie BRD
 Director/Board Member 39 30/03/21
Ming Jin BRD
 Director/Board Member 50 30/03/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 264,648,217 0 0 56.11 %
Stock B 1 1,497,934,235 989,042,031 ( 66.03 %) 0

Shareholders

NameEquities%Valuation
HHLR Advisors Ltd.
13.93 %
208,671,222 13.93 % 124 M $
Pang Kee Hebert Chan
10.59 %
158,588,612 10.59 % 94 M $
Vivo Capital LLC
8.225 %
123,198,118 8.225 % 73 M $
Zhao Renbin
7.800 %
116,839,593 7.800 % 69 M $
Jisong Cui
6.691 %
100,222,916 6.691 % 60 M $
TMF Group BV
5.942 %
89,014,653 5.942 % 53 M $
Loyal Valley Capital Co. Ltd.
3.479 %
52,120,614 3.479 % 31 M $
GIC Pte Ltd. (Investment Management)
2.347 %
35,154,419 2.347 % 21 M $
Bosera Asset Management Co., Ltd.
0.5464 %
8,184,000 0.5464 % 5 M $
Ze Min Zhang
0.4480 %
6,711,111 0.4480 % 4 M $
NameEquities%Valuation
Penghua Fund Management Co., Ltd.
12.13 %
31,553,245 12.13 % 42 M $
Wanjia Asset Management Co., Ltd.
7.687 %
20,000,000 7.687 % 26 M $
City of Guangzhou
3.450 %
8,975,521 3.450 % 12 M $
Bank of China Investment Management Co., Ltd.
3.248 %
8,449,578 3.248 % 11 M $
ICBC Credit Suisse Asset Management Co., Ltd.
2.697 %
7,017,900 2.697 % 9 M $
Yong Tao Guo
2.306 %
6,000,000 2.306 % 8 M $
Beijing Gao Hua Shengzi Investment Management Co. Ltd.
2.225 %
5,789,170 2.225 % 8 M $
Morgan Stanley Investment Management Ltd.
2.208 %
5,745,424 2.208 % 8 M $
China Fund Management Co., Ltd.
1.345 %
3,500,000 1.345 % 5 M $
China Asset Management Co., Ltd.
1.322 %
3,439,169 1.322 % 5 M $

Company contact information

InnoCare Pharma Ltd.

Building 8, Changping District No. 8 Life Science Park Road

100084, Beijing

+86 10 6660 9999

http://www.innocarepharma.com
address InnoCare Pharma Limited(9969)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for InnoCare Pharma Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.285 CNY
Average target price
8.987 CNY
Spread / Average Target
+109.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INNOCARE PHARMA LIMITED Stock InnoCare Pharma Limited
-23.95% 1.2B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+3.87% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-8.61% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 9969 Stock
  4. Company InnoCare Pharma Limited